Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease.

NCT00431249 is registered in ClinicalTrials.gov with Tungs' Taichung Metroharbour Hospital as lead sponsor.

NCT NCT00431249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease.
Lead sponsor
Tungs' Taichung Metroharbour Hospital
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2007
Completion date
April 30, 2008
Enrollment
40 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis patients, peripheral vascular disease